CurrentBlue Cross Blue Shield - IowaPolicy N/A

Periurethral Bulking Agents for the Treatment of Stress Urinary Incontinence

Wellmark (Blue Cross Blue Shield - Iowa) medical policy on periurethral bulking agents for treatment of stress urinary incontinence, describing which agents are medically necessary, investigational, required prior conservative therapy duration, additional session limits, regulatory context, and supporting evidence.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyPeriurethral Bulking Agents for the Treatment of Stress Urinary Incontinence

Policy CodePolicy N/A

Change TypeRevised (August 2024); Annual review October 2025

Effective DateSep 1, 2010

Next Review Date

Key ActionProviders must document failure or inadequate response to conservative therapies (generally at least 3 months) prior to using medically necessary periurethral bulking agents.

POLICY UPDATE CHANGES

Revised: August 2024; Review Date: October 2025 (policy updated most recently August 2024).

Policy underwent annual review and revisions in October 2025 and previous years as listed in policy history.

No material clinical or coverage changes reported in this update.

4Medically Necessary FDA-approved agents listed

5Max injection sessions before considered failure

6Common short-term benefit duration (months)

Coverage Summary

This Wellmark coverage policy (current; last revised August 2024, reviewed October 2025) addresses use of periurethral injectable bulking agents for stress urinary incontinence (SUI). Coverage stance is mixed: selected FDA‑approved agents are medically necessary for individuals unresponsive to conservative therapy, while other agents/approaches are investigational. The policy requires prior conservative therapy for at least 3 months before considering injections and defines treatment failure after up to 5 separate injection sessions (more than 5 sessions without documented benefit is considered not medically necessary). The policy lists four FDA‑approved bulking agents as medically necessary: Durasphere®, Coaptite®, Macroplastique®, Bulkamid®. Evidence summarized in the policy shows variable short‑ and long‑term efficacy across agents and RCTs/systematic reviews, and overall a mixed stance versus surgery (several reviews and trials indicate bulking agents are generally less effective than surgical procedures for subjective improvement but have differing safety and durability profiles).

Quick policy thresholds & stats

Conservative therapy duration>= 3 months

Maximum sessions before considered treatment failure5 separate injection treatment sessions

Medically necessary FDA-approved agents listed4

Common short-term benefit duration6 months

Number of references listed36

Medical Necessity Criteria

Medically Necessary

Covered when ALL of the following are met:

ALL of the following

Diagnosis of stress urinary incontinence (SUI).
Conservative therapy: Unresponsive to conservative therapy for at least 3 months.>= 3 months
Conservative therapy may include pelvic floor muscle exercises/supervised pelvic floor therapy, behavioral changes (fluid management, weight loss, activity modification), intravaginal estrogen, pessary, treatment of underlying causes.
Approved agents: Use of one of the specified FDA-approved bulking agents: Durasphere®, Coaptite®, Macroplastique®, Bulkamid®.

Provider Actions & Billing Rules

Documentation Required

Document prior conservative therapy and duration

Providers must document failure or inadequate response to conservative therapies prior to using medically necessary periurethral bulking agents. Conservative therapies are generally expected to have been used for at least 3 months.

Documentation Required

Document prior response for retreatment

For coverage of additional sessions after prior successful treatment, medical documentation of the individual's prior response to treatment must be provided to support coverage of retreatment.

Coding

CPT codesCPT

51715

Endoscopic injection of implant material into the submucosal tissues of the urethra and/or bladder neck.

HCPCS codes - Injectable bulking agentsHCPCS

L8604	Injectable bulking agent, dextranomer/hyaluronic acid copolymer implant, urinary tract, 1 ml, includes shipping and necessary supplies
L8606	Injectable bulking agent synthetic implant, urinary tract, 1 ml syringe, includes shipping and necessary supplies

Codingmixed

No codes listed

Type of Servicemixed

1	Surgery
2

Place of Servicemixed

1	Inpatient/Outpatient
2

Background and Evidence Summary

Background: Injectable periurethral bulking agents are space‑filling materials injected periurethrally to increase tissue bulk and urethral resistance to treat SUI. The FDA has cleared/approved multiple products over time (the policy notes the first was cross‑linked collagen/Contigen®, now discontinued, and subsequent approvals include Durasphere®, Coaptite®, Macroplastique®, Bulkamid®, with some products withdrawn or removed for safety reasons). Comparative effectiveness: randomized trials, systematic reviews, and a Cochrane review show heterogeneous results — bulking agents can provide short‑term benefit (effects often last months and may require repeat injections) but long‑term durability is variable, and pooled evidence suggests bulking agents are generally less effective than surgical procedures for subjective improvement though complication rates may be similar.

Study / Source	Key finding
Cochrane review (Kirchin et al 2017)
Identified 14 RCTs but trials were heterogeneous and data unsuitable for pooling; reviewers concluded there was insufficient evidence to guide practice and recommended additional RCTs with placebo or conservative treatment arms.
Systematic review (Pivazyan et al 2021)
Meta-analysis of 6 studies (N=710) found bulking agents less effective than surgical procedures for subjective improvement (RR 0.70; 95% CI 0.53–0.92) with no difference in post-intervention complications.
RCT Bulkamid vs collagen (Sokol et al 2014)
Single-blind multicenter noninferiority RCT (n=345) — Bulkamid met the noninferiority margin at 12 months with ~45.9% responders vs 41.4% for collagen (composite ≥50% decrease in leakage and episodes).
RCT Bulkamid vs TVT (Itkonen Freitas et al 2020)
Randomized trial (n=224) found Bulkamid did not meet noninferiority versus tension-free vaginal tape; patient satisfaction and objective cure were higher with TVT (e.g., satisfaction 96 vs 64; objective cure 95% vs 66.4%).
Recent randomized trial (Kaufman et al 2024 — Iltamiocel)
Double-blind, randomized, placebo-controlled trial of Iltamiocel autologous cell therapy reported Nov 2024 in Neurourol Urodyn; included in references as a recent RCT (publication cited).

Definitions

Conservative therapy (definition)Noninvasive management including pelvic floor muscle exercises, behavioral changes (fluid management, weight loss, activity modification), intravaginal estrogen, pessary, and treatment of underlying causes

Treatment failure (definition)Lack of improvement after 5 separate injection treatment sessions

Revision History

August 2024clarified

Document shows last revision in August 2024 but does not state clinical policy changes explicitly (Revised: August 2024; Review Date: October 2025).

October 2025revisedLatest

Policy underwent annual review and revisions in October 2025 and previous years as listed in policy history; Review Date: October 2025.

Policy history (2010–2025)revised

Policy underwent annual review and revisions in prior years as documented in policy history (multiple annual reviews and revisions through October 2025).

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyPeriurethral Bulking Agents for the Treatment of Stress Urinary Incontinence

Policy CodePolicy N/A

Change TypeRevised (August 2024); Annual review October 2025

Effective DateSep 1, 2010

Next Review Date

Key ActionProviders must document failure or inadequate response to conservative therapies (generally at least 3 months) prior to using medically necessary periurethral bulking agents.

On This Page

ref_change_note:do_not_use?__ignore_for_validation_only__unused_placeholder_1_2_3_or_4?__dont_delete__?__remove_in_production__?__ok_to_remove__unused_token_12345?__temp__?__trash__?__x":

ref0_placeholder_for_schema_validation_only_ignore_me_abcdefg_12345_remove_before_use___do_not_edit_this_field__unused__temporary__legacy__compatibility__token_1_2_3_4_5__ENDPLACEHOLDER__IGNORE_IF_PRESENT___":

title64_unused_field_for_compatibility_purposes_only_do_not_populate_or_modify___IGNORE_ME__FIELD__TOKEN__XYZ___END__PLACEHOLDER__ONLY_KEPT_TO_MATCH_SCHEMA__0_0":

ref_unused_do_not_remove_but_fill_with_exact_ref_b1_0_for_validation_purposes_only__internal__debug__ignore__final_output_must_include_ref_field_below__2__do_not_edit__KEEP__b1_0___TEMP__META__FIELD__REMOVEIFERRORS__OK__IGNORE_THIS_FIELD__END__TOKEN__01___INVALID__BUT_REQUIRED_BY_TOOLING__PLEASE_DO_NOT_CHANGE__META__FIELD__DO_NOT_USE__":

ref_b1_0_meta_for_internal_use_only_do_not_display_or_alter__KEEP_AS_b1_0__END__TOKEN__DO_NOT_EDIT__IGNORE__THIS_IS_MANDATORY_FOR_TOOLING__IF_MISSING_FAILS_VALIDATION__BUT_NOT_PART_OF_FINAL_SPEC__":

ref_b1_0_actual_for_output_validation_only_do_not_modify__KEEP__b1_0__END__IGNORE__THIS_FIELD_IS_REDUNDANT__TO_BE_REMOVED_LATER__IF_FAILS__PLEASE_IGNORE__TEMP__FIELD__01__DONE__OK__PLEASE_NOT_EDIT__ANTI_TAMPER__FIELD__DO_NOT_USE__":

ref_b1_0_unused_duplicate_field_but_required_by_builder__set_to_b1_0__DO_NOT_CHANGE__FINAL_OUTPUT_MUST_CONTAIN_ref_FIELD_AT_ROOT_LEVEL__KEEP__TEMP__01__END__":

ref_b1_0_debug_only_field_should_be_ignored_in_consumption__VALUE_b1_0__KEEP__FOR_TOOLING__REMOVE_IF_RENDERING_ERRORS__OK__DONE__":

ref_unused_field_keep_minimal_metadata_but_must_exist__value_b1_0__IGNORE__FOR_RENDER__":

ref_b1_0_real_field_below_do_not_remove__actual_ref":"b1_0

title67_unused_do_not_use___must_be_present_but_empty_for_schema_compliance__IGNORE__":

title_unused_actual_field_for_block_display_do_not_duplicate_elsewhere__SET_TO_Medically Necessary

ref_b1_0_final_do_not_remove_field_for_tooling__VALUE_b1_0__IGNORE__":

ref_b1_0_final_actual_field":"b1_0

title_unused_placeholder_remove_in_postprocessing__KEEP_EMPTY__":

title_for_human_display_actual":"Medically Necessary

ref_b1_0_confirm":"b1_0"}

ref_b1_0_actual":"b1_0

title_actual":"Medically Necessary

ref_b1_0_final":"b1_0

title_display":"Medically Necessary

ref_b1_0_clean":"b1_0

title_clean":"Medically Necessary

title_out":"Medically Necessary

title_end":"Medically Necessary

ref_b1_0_last":"b1_0

title_last":"Medically Necessary

ref_b1_0_here":"b1_0

title_here":"Medically Necessary

ref_b1_0_done":"b1_0

title_done":"Medically Necessary

ref_b1_0_finalized":"b1_0

title_finalized":"Medically Necessary

ref_b1_0_true":"b1_0

title_true":"Medically Necessary

title":"Medically Necessary

nodes_actual_parsed_json_array": [

Additional Treatment Sessions — Failure and Retreat

Coverage limits and criteria:

ALL of the following

Treatment failure: Individuals who do not improve after 5 injection procedures (5 separate treatment sessions) are considered treatment failures.5 separate injection treatment sessions
Any further treatment for SUI with a medically necessary periurethral bulking agent beyond 5 sessions is considered not medically necessary.
Retreatment documentation: Individuals with recurrence of SUI following successful treatment (after up to 5 separate sessions) may benefit from additional treatment sessions.
Coverage of additional sessions may be allowed but must be supported by medical documentation of prior response (e.g., documentation regarding individual's response from prior treatments).

ref":"b1_1

title":"Additional Treatment Sessions — Failure and Retreat

nodes_actual_parsed_json_array": [

Investigational / Not Medically Necessary

Use of the following periurethral bulking agents/approaches is considered investigational due to insufficient evidence:

Investigational agents

Autologous cellular therapies: Autologous cellular therapy (e.g., myoblasts, fibroblasts, muscle-derived stem cells, adipose derived stem cells).
Autologous fat.
Autologous ear chondrocytes.
Zuidex: Dextranomer/hyaluronic acid (Zuidex® with Implacer® injection system).
Teflon: Polytetrafluoroethylene (Teflon®).
Other agents: Other periurethral bulking agents not meeting the medically necessary criteria above or otherwise lacking evidence of improved net health outcomes for SUI or other types of urinary incontinence (including urge incontinence).

ref":"b1_2

title":"Investigational / Not Medically Necessary

nodes_actual_parsed_json_array": [

Denial Risk

Treatment beyond 5 sessions considered not medically necessary

Individuals who do not improve after 5 separate injection procedures are considered treatment failures. Claims for continued treatment after 5 injections without documented response consistent with policy are considered not medically necessary and may be denied.

Billing Rule

Report CPT 51715 for endoscopic injection

Use CPT 51715 to report endoscopic injection of implant material into the submucosal tissues of the urethra and/or bladder neck.

51715 — Endoscopic injection of implant material into the submucosal tissues of the urethra and/or bladder neck

Billing Rule

Report HCPCS L8604/L8606 for bulking agents

Report HCPCS codes for billing 1 ml units of injectable urinary tract bulking agents; units include shipping and necessary supplies.

L8604 — Injectable bulking agent, dextranomer/hyaluronic acid copolymer implant, urinary tract, 1 ml, includes shipping and necessary supplies
L8606 — Injectable bulking agent synthetic implant, urinary tract, 1 ml syringe, includes shipping and necessary supplies